Kairos Pharma Ltd. has received a Department of Defense grant to further its lung cancer biomarker research, advancing the company's strategic efforts to develop innovative cancer therapies. The grant supports the company's lead candidate ENV105, an antibody targeting CD105, a protein critical in cancer drug resistance.
The company is currently conducting two clinical trials for ENV105, targeting prostate and EGFR-dependent non-small cell lung cancers. Safety and interim efficacy results are anticipated in the second quarter of 2025. This research represents a significant step in addressing challenging treatment resistance mechanisms in oncology.
ENV105 aims to reverse drug resistance by targeting CD105, potentially restoring the effectiveness of standard cancer therapies across multiple cancer types. The research focuses on a key challenge in cancer treatment: the tendency of tumors to develop resistance to existing therapies.
Kairos Pharma's approach is supported by a robust intellectual property portfolio extending into the 2030s and has garnered analyst coverage from firms including EF Hutton and HC Wainwright. The non-dilutive government grant underscores the potential scientific and medical significance of the company's research.
The development of ENV105 represents a promising approach to addressing significant unmet medical needs in cancer treatment, particularly in prostate and lung cancer. By targeting CD105, the therapy seeks to overcome a critical limitation in current cancer treatments and potentially improve patient outcomes.
